Paul A.P.A.CarpenterPaul A.P.A. i inni, A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease, „Blood”, 99 (8), 2002, s. 2712-279, DOI: 10.1182/blood.V99.8.2712, PMID: 11929757.
Daniel C.D.C.BaumgartDaniel C.D.C., William J.W.J.SandbornWilliam J.W.J., Inflammatory bowel disease: clinical aspects and established and evolving therapies, „The Lancet”, 369 (9573), 2007, s. 1641-1657, DOI: 10.1016/S0140-6736(07)60751-X, PMID: 17499606.
Pieter C.F.P.C.F.StokkersPieter C.F.P.C.F., Daniel W.D.W.HommesDaniel W.D.W., Novel biological therapies for inflammatory bowel disease, „Current Treatment Options in Gastroenterology”, 9 (3), 2006, s. 201-210, DOI: 10.1007/s11938-006-0039-y, PMID: 16901384.
Paul A.P.A.CarpenterPaul A.P.A. i inni, A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease, „Blood”, 99 (8), 2002, s. 2712-279, DOI: 10.1182/blood.V99.8.2712, PMID: 11929757.
Daniel C.D.C.BaumgartDaniel C.D.C., William J.W.J.SandbornWilliam J.W.J., Inflammatory bowel disease: clinical aspects and established and evolving therapies, „The Lancet”, 369 (9573), 2007, s. 1641-1657, DOI: 10.1016/S0140-6736(07)60751-X, PMID: 17499606.
Pieter C.F.P.C.F.StokkersPieter C.F.P.C.F., Daniel W.D.W.HommesDaniel W.D.W., Novel biological therapies for inflammatory bowel disease, „Current Treatment Options in Gastroenterology”, 9 (3), 2006, s. 201-210, DOI: 10.1007/s11938-006-0039-y, PMID: 16901384.